Verrica Pharmaceuticals (VRCA) Liabilities and Shareholders Equity (2017 - 2026)

Verrica Pharmaceuticals' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $38.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 8.04% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at $165.9 million (down 8.46% YoY), while the FY2025 annual figure was $47.1 million, down 12.94% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $38.8 million, down from $47.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $97.1 million in Q3 2023, with the low at $32.9 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $52.0 million (2024), against an average of $56.0 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity soared 97.67% in 2023, then tumbled 66.11% in 2024.
• Verrica Pharmaceuticals' Liabilities and Shareholders Equity stood at $44.7 million in 2022, then soared by 82.46% to $81.6 million in 2023, then plunged by 33.66% to $54.1 million in 2024, then decreased by 12.94% to $47.1 million in 2025, then retreated by 17.71% to $38.8 million in 2026.
• Business Quant data shows VRCA's Liabilities and Shareholders Equity at $38.8 million in Q1 2026, $47.1 million in Q4 2025, and $40.9 million in Q3 2025.